Patents by Inventor Peter Johannes GOEDINGS

Peter Johannes GOEDINGS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Duocarmycin ADCs showing improved in vivo antitumor activity
    Patent number: 11382982
    Abstract: The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumours and haematological malignancies expressing HER2, in particular breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer or osteosarcoma, and acute lymphoblastic leukaemia. In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of human solid tumours with HER2 IHC 2+ or 1+ and HER2 FISH negative tissue status. Advantageously, the present invention relates to duocarmycin-containing ADCs for use in the treatment of triple negative breast cancer (TNBC).
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: July 12, 2022
    Assignee: Byondis B.V.
    Inventors: Willem Dokter, Peter Johannes Goedings, Gijsbertus Franciscus Maria Verheijden, Patrick Henry Beusker
  • Duocarmycin ADCs showing improved in vivo antitumor activity
    Patent number: 10603387
    Abstract: The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumours and haematological malignancies expressing HER2, in particular breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer or osteosarcoma, and acute lymphoblastic leukaemia. In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of human solid tumours with HER2 IHC 2+ or 1+ and HER2 FISH negative tissue status. Advantageously, the present invention relates to duocarmycin-containing ADCs for use in the treatment of triple negative breast cancer (TNBC).
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: March 31, 2020
    Assignee: Synthon Biopharmaceuticals B.V.
    Inventors: Willem Dokter, Peter Johannes Goedings, Gijsbertus Franciscus Maria Verheijden, Patrick Henry Beusker
  • DUOCARMYCIN ADCS SHOWING IMPROVED IN VIVO ANTITUMOR ACTIVITY
    Publication number: 20190314513
    Abstract: The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumours and haematological malignancies expressing HER2, in particular breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer or osteosarcoma, and acute lymphoblastic leukaemia. In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of human solid tumours with HER2 IHC 2+ or 1+ and HER2 FISH negative tissue status. Advantageously, the present invention relates to duocarmycin-containing ADCs for use in the treatment of triple negative breast cancer (TNBC).
    Type: Application
    Filed: June 28, 2019
    Publication date: October 17, 2019
    Inventors: Willem DOKTER, Peter Johannes GOEDINGS, Gijsbertus Franciscus Maria VERHEIJDEN, Patrick Henry BEUSKER
  • Duocarmycin ADCs for use in treatment of endometrial cancer
    Patent number: 10092659
    Abstract: The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumors expressing HER2, wherein the human solid tumor expressing HER2 is endometrial cancer, in particular uterine serous carcinoma (USC). In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of endometrial cancer, notably USC, with HER2 IHC 2? or 1+ and HER2 FISH negative tumor tissue status.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: October 9, 2018
    Assignees: Synthon Biopharmaceuticals B.V., Yale University
    Inventors: Alessandro Davide Santin, Peter Johannes Goedings
  • DUOCARMYCIN ADCS SHOWING IMPROVED IN VIVO ANTITUMOR ACTIVITY
    Publication number: 20180140711
    Abstract: The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumours and haematological malignancies expressing HER2, in particular breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer or osteosarcoma, and acute lymphoblastic leukaemia. In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of human solid tumours with HER2 IHC 2+ or 1+ and HER2 FISH negative tissue status. Advantageously, the present invention relates to duocarmycin-containing ADCs for use in the treatment of triple negative breast cancer (TNBC).
    Type: Application
    Filed: October 31, 2017
    Publication date: May 24, 2018
    Applicant: Synthon Biopharmaceuticals B.V.
    Inventors: Willem Dokter, Peter Johannes Goedings, Gijsbertus Franciscus Maria Verheijden, Patrick Henry Beusker
  • DUOCARMYCIN ADCS SHOWING IMPROVED IN VIVO ANTITUMOR ACTIVITY
    Publication number: 20170014525
    Abstract: The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumours and haematological malignancies expressing HER2, in particular breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer or osteosarcoma, and acute lymphoblastic leukaemia. In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of human solid tumours with HER2 IHC 2+ or 1+ and HER2 FISH negative tissue status. Advantageously, the present invention relates to duocarmycin-containing ADCs for use in the treatment of triple negative breast cancer (TNBC).
    Type: Application
    Filed: July 21, 2016
    Publication date: January 19, 2017
    Applicant: Synthon Biopharmaceuticals B.V.
    Inventors: Willem DOKTER, Peter Johannes GOEDINGS, Gijsbertus Franciscus Maria VERHEIJDEN, Patrick Henry BEUSKER
  • DUOCARMYCIN ADCS FOR USE IN TREATMENT OF ENDOMETRIAL CANCER
    Publication number: 20170007717
    Abstract: The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumours expressing HER2, wherein the human solid tumour expressing HER2 is endometrial cancer, in particular uterine serous carcinoma (USC). In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of endometrial cancer, notably USC, with HER2 IHC 2? or 1+ and HER2 FISH negative tumour tissue status.
    Type: Application
    Filed: July 21, 2016
    Publication date: January 12, 2017
    Applicants: Synthon Biopharmaceuticals B.V., Yale University
    Inventors: Alessandro Davide SANTIN, Peter Johannes GOEDINGS
  • Duocarmycin ADCs for use in treatment of endometrial cancer
    Patent number: 9427480
    Abstract: The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumors expressing HER2, wherein the human solid tumor expressing HER2 is endometrial cancer, in particular uterine serous carcinoma (USC). In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of endometrial cancer, notably USC, with HER2 IHC 2? or 1+ and HER2 FISH negative tumor tissue status.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: August 30, 2016
    Assignees: Synthon Biopharmaceuticals B.V., Yale University
    Inventors: Alessandro Davide Santin, Peter Johannes Goedings
  • Duocarmycin ADCS showing improved in vivo antitumor activity
    Patent number: 9421278
    Abstract: The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumors and haematological malignancies expressing HER2, in particular breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer or osteosarcoma, and acute lymphoblastic leukaemia. In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of human solid tumors with HER2 IHC 2+ or 1+ and HER2 FISH negative tissue status. Advantageously, the present invention relates to duocarmycin-containing ADCs for use in the treatment of triple negative breast cancer (TNBC).
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: August 23, 2016
    Assignee: Synthon Biopharmaceuticals B.V.
    Inventors: Willem Dokter, Peter Johannes Goedings, Gijsbertus Franciscus Maria Verheijden, Patrick Henry Beusker
  • DUOCARMYCIN ADCS FOR USE IN TREATMENT OF ENDOMETRIAL CANCER
    Publication number: 20160008487
    Abstract: The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumours expressing HER2, wherein the human solid tumour expressing HER2 is endometrial cancer, in particular uterine serous carcinoma (USC). In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of endometrial cancer, notably USC, with HER2 IHC 2? or 1+ and HER2 FISH negative tumour tissue status.
    Type: Application
    Filed: September 18, 2015
    Publication date: January 14, 2016
    Inventors: Alessandro Davide SANTIN, Peter Johannes GOEDINGS
  • DUOCARMYCIN ADCS SHOWING IMPROVED IN VIVO ANTITUMOR ACTIVITY
    Publication number: 20160008486
    Abstract: The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumours and haematological malignancies expressing HER2, in particular breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer or osteosarcoma, and acute lymphoblastic leukaemia. In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of human solid tumours with HER2 IHC 2+ or 1+ and HER2 FISH negative tissue status. Advantageously, the present invention relates to duocarmycin-containing ADCs for use in the treatment of triple negative breast cancer (TNBC).
    Type: Application
    Filed: September 18, 2015
    Publication date: January 14, 2016
    Applicant: Synthon Biopharmaceuticals B.V.
    Inventors: Willem DOKTER, Peter Johannes GOEDINGS, Gijsbertus Franciscus Maria VERHEIJDEN, Patrick Henry BEUSKER